drugset / Trial / NCT07168018
Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II randomised, open-label study to assess the safety and immunogenicity of coadministration of the candidate rabies vaccine ChAdOx2 RabG and licensed vaccine in healthy adults (18-45 years old). ChAdOx2 RabG will be administered intramuscularly and licensed rabies vaccine will be given either intramuscularly (i.e., for the intervention group) or by intradermal injection (i.e., for the control group).
Timeline
- Start
- 2025-12
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAdOx2 RabG | Vaccine | 5e+10 vg | Intramuscular |
| Comparator | Inactivated Rabies Vaccine | Vaccine | — | Intramuscular |